Development of radioligands for the imaging of α7 nicotinic acetylcholine receptors with positron emission tomography

Current Drug Targets

Volumn 13, Issue 5, 2012, Pages 594-601

  Brust, Peter ^a   Peters, Dan ^b   Deuther Conrad, Winnie ^a  

^a INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^b NEUROSEARCH A S   (Denmark)

Author keywords

Drug design; Molecular imaging; Neurodegeneration; Nicotine; Orthosteric ligand

Indexed keywords

3 (2 AZETIDINYLMETHOXY)PYRIDINE; BUNGAROTOXIN RECEPTOR; RADIOLIGAND; TRACER;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN REGION; DRUG DESIGN; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; MEMBRANE PERMEABILITY; MOLECULAR IMAGING; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTEIN TARGETING; RADIOACTIVITY;

EID: 84860474960     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012800398955     Document Type: Article

References (101)

1. 2+ stores. J Neurochem 2002; 81: 606-14.
2. Sharma G, Vijayaraghavan S. Nicotinic cholinergic signaling in hippocampal astrocytes involves calcium-induced calcium release from intracellular stores. Proc Natl Acad Sci U S A 2001; 98: 4148-53.
3. Gilbert D, Lecchi M, Arnaudeau S, Bertrand D, Demaurex N. Local and global calcium signals associated with the opening of neuronal α7 nicotinic acetylcholine receptors. Cell Calcium 2009; 45: 198-207.
4. Shen JX, Yakel JL. Nicotinic acetylcholine receptor-mediated calcium signaling in the nervous system. Acta Pharmacol Sin 2009; 30: 673-80.
5. Leonard S. Consequences of low levels of nicotinic acetylcholine receptors in schizophrenia for drug development. Drug Develop Res 2003; 60: 127-36.
6. Radcliffe KA, Dani JA. Nicotinic stimulation produces multiple forms of increased glutamatergic synaptic transmission. J Neurosci 1998; 18: 7075-83.
7. Albuquerque EX, Alkondon M, Pereira EF, et al. Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther 1997; 280: 1117-36.
8. Liu Y, Ford B, Mann MA, Fischbach GD. Neuregulins increase α7 nicotinic acetylcholine receptors and enhance excitatory synaptic transmission in GABAergic interneurons of the hippocampus. J Neurosci 2001; 21: 5660-9.
9. Fu Y, Matta SG, Sharp BM. Local α-bungarotoxin-sensitive nicotinic receptors modulate hippocampal norepinephrine release by systemic nicotine. J Pharmacol Exp Ther 1999; 289: 133-9.
10. Li X, Rainnie DG, McCarley RW, Greene RW. Presynaptic nicotinic receptors facilitate monoaminergic transmission. J Neurosci 1998; 18: 1904-12.
11. Kulak JM, Nguyen TA, Olivera BM, McIntosh JM. Alphaconotoxin MII blocks nicotine-stimulated dopamine release in rat striatal synaptosomes. J Neurosci 1997; 17: 5263-70.
12. Northrop NA, Smith LP, Yamamoto BK, Eyerman DJ. Regulation of glutamate release by alpha7 nicotinic receptors: differential role in methamphetamine-induced damage to dopaminergic and serotonergic terminals. J Pharmacol Exp Ther 2011; 336: 900-7.
13. Tani Y, Saito K, Imoto M, Ohno T. Pharmacological characterization of nicotinic receptor-mediated acetylcholine release in rat brain--an in vivo microdialysis study. Eur J Pharmacol 1998; 351: 181-8.
14. Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res 2011; 221: 555-63.
15. Galindo-Charles L, Hernandez-Lopez S, Galarraga E, et al. Serotoninergic dorsal raphe neurons possess functional postsynaptic nicotinic acetylcholine receptors. Synapse 2008; 62: 601-15.
16. Stella N, Piomelli D. Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur J Pharmacol 2001; 425: 189-96.
17. van der Stelt M, Di Marzo V. Anandamide as an intracellular messenger regulating ion channel activity. Prostaglandins Other Lipid Mediat 2005; 77: 111-22.
18. McPartland JM, Blanchon DJ, Musty RE. Cannabimimetic effects modulated by cholinergic compounds. Addiction Biol 2008; 13: 411-5.
19. Hagooly A, Rossin R, Welch MJ. Small molecule receptors as imaging targets. Handb Exp Pharmacol 2008; (185 pt 2): 93-129.
20. Antoni G, Langström B. Radiopharmaceuticals: molecular imaging using positron emission tomography. Handb Exp Pharmacol 2008; (185 pt 1): 177-201.
21. Heiss WD, Herholz K. Brain receptor imaging. J Nucl Med 2006; 47: 302-12.
22. Spanoudaki VC, Ziegler SI. PET & SPECT instrumentation. Handb Exp Pharmacol 2008; 53-74.
23. Galban CJ, Galban S, Van Dort ME, et al. Applications of molecular imaging. Prog Mol Biol Transl Sci 2010; 95: 237-98.
24. Xi W, Tian M, Zhang H. Molecular imaging in neuroscience research with small-animal PET in rodents. Neurosci Res 2011; 70: 133-43.
25. Lancelot S, Zimmer L. Small-animal positron emission tomography as a tool for neuropharmacology. Trends Pharmacol Sci 2010; 31: 411-7.
26. Wienhard K, Schmand M, Casey ME, et al. The ECAT HRRT: Performance and first clinical application of the new high resolution research tomograph. Ieee T Nucl Sci 2002; 49: 104-10.
27. Heiss WD, Habedank B, Klein JC, et al. Metabolic rates in small brain nuclei determined by high-resolution PET. J Nucl Med 2004; 45: 1811-5.
28. Lecomte R. Novel detector technology for clinical PET. Eur J Nucl Med Mol I 2009; 36 Suppl 1: S69-85.
29. Slomka PJ, Baum RP. Multimodality image registration with software: state-of-the-art. Eur J Nucl Med Mol I 2009; 36 Suppl 1: S44-55.
30. Heiss WD. The potential of PET/MR for brain imaging. Eur J Nucl Med Mol I 2009; 36 Suppl 1: S105-12.
31. Mawlawi O, Townsend DW. Multimodality imaging: an update on PET/CT technology. Eur J Nucl Med Mol I 2009; 36 Suppl 1: S15-29.
32. von Schulthess GK, Schlemmer HP. A look ahead: PET/MR versus PET/CT. Eur J Nucl Med Mol I 2009; 36 Suppl 1: S3-9.
33. Davson H, Segal MB. Physiology of the CSF and blood-brain barriers. Boca Raton, USA: CRC Press 1996.
34. Liu X, Testa B, Fahr A. Lipophilicity and its relationship with passive drug permeation. Pharm Res 2011; 28: 962-77.
35. Waterhouse RN. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 2003; 5: 376-89.
36. Toyohara J, Wu J, Hashimoto K. Recent development of radioligands for imaging α7 nicotinic acetylcholine receptors in the brain. Curr Top Med Chem 2010; 10: 1544-57.
37. Ulens C, Akdemir A, Jongejan A, et al. Use of acetylcholine binding protein in the search for novel alpha7 nicotinic receptor ligands. In silico docking, pharmacological screening, and X-ray analysis. J Med Chem 2009; 52: 2372-83.
38. Hajos M, Rogers BN. Targeting alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia. Curr Pharm Des 2010; 16: 538-54.
39. Mullen G, Napier J, Balestra M, et al. (-)-Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the α7 nicotinic acetylcholine receptor. J Med Chem 2000; 43: 4045-50.
40. Dolle F, Valette H, Hinnen F, et al. Synthesis and preliminary evaluation of a carbon-11-labelled agonist of the α7 nicotinic acetylcholine receptor. J Labelled Compd Rad 2001; 44: 785-95.
41. Pomper MG, Phillips E, Fan H, et al. Synthesis and biodistribution of radiolabeled α7 nicotinic acetylcholine receptor ligands. J Nucl Med 2005; 46: 326-34.
42. de Fiebre CM, Meyer EM, Henry JC, Muraskin SI, Kem WR, Papke RL. Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative is a selective agonist at neuronal nicotinic α7/125I-alphabungarotoxin receptor subtypes. Mol Pharmacol 1995; 47: 164-71.
43. Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an α7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006; 63: 630-8.
44. Kim SW, Ding YS, Alexoff D, et al. Synthesis and positron emission tomography studies of C-11-labeled isotopomers and metabolites of GTS-21, a partial alpha7 nicotinic cholinergic agonist drug. Nucl Med Biol 2007; 34: 541-51.
45. Bunnelle WH, Dart MJ, Schrimpf MR. Design of ligands for the nicotinic acetylcholine receptors: the quest for selectivity. Curr Top Med Chem 2004; 4: 299-334.
46. [11C]CHIBA-1001 as a novel PET ligand for α7 nicotinic receptors in the brain: a PET study in conscious monkeys. PLoS ONE 2008; 3: e3231.
47. 11C]CHIBA-1001 for mapping α7 nicotinic receptors by positron emission tomography. Ann Nucl Med 2009; 23: 301-9.
48. 11C]CHIBA-1001 in humans. Nucl Med Biol 2011; 38: 443-8.
49. Peters D, Olsen GM, Nielsen EO, et al. Novel 1,4-diazabicyclo[ 3.2.2]nonyl oxadiazolyl derviatives and their medical use, WO/2007/138037. 2007.
50. 11C]NS-12857: A novel PET ligand for α7-nicotinergic receptors. J Labelled Compd Rad 2009; 52: S379-S.
51. 18F]NS10743. Eur J Nucl Med Mol Imaging 2011; 38: 1541-9.
52. 11C]NS14492 as a novel PET ligand for imaging cerebral α7 nicotinic receptors: in vivo evaluation and drug occupancy measurements. J Nucl Med 2011: in press.
53. Liu X, Chen C, Smith BJ. Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther 2008; 325: 349-56.
54. Summerfield SG, Read K, Begley DJ, et al. Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther 2007; 322: 205-13.
55. Tresadern G, Bartolome JM, Macdonald GJ, Langlois X. Molecular properties affecting fast dissociation from the D2 receptor. Bioorg Med Chem 2011; 19: 2231-41.
56. Meyer PM, Strecker K, Kendziorra K, et al. Reduced α4β2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry 2009; 66: 866-77.
57. Kendziorra K, Wolf H, Meyer PM, et al. Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. Eur J Nucl Med Mol Imaging 2011; 38: 515-25.
58. Sabri O, Kendziorra K, Wolf H, Gertz HJ, Brust P. Acetylcholine receptors in dementia and mild cognitive impairment. Eur J Nucl Med Mol Imaging 2008; 35 Suppl 1: S30-45.
59. 125I] alpha-bungarotoxin binding. J Chem Neuroanat 1997; 13: 105-13.
60. Terry AV, Jr, Parikh V, et al. Time-dependent effects of haloperidol and ziprasidone on nerve growth factor, cholinergic neurons, and spatial learning in rats. J Pharmacol Exp Ther 2006; 318: 709-24.
61. Stolerman IP. Behavioural pharmacology of nicotine: implications for multiple brain nicotinic receptors. Ciba Found Symp 1990; 152: 3-16; discussion -22.
62. Nomikos GG, Schilström B, Hildebrand BE, Panagis G, Grenhoff J, Svensson TH. Role of α7 nicotinic receptors in nicotine dependence and implications for psychiatric illness. Behav Brain Res 2000; 113: 97-103.
63. Small E, Shah HP, Davenport JJ, et al. Tobacco smoke exposure induces nicotine dependence in rats. Psychopharmacology (Berl) 2010; 208: 143-58.
64. Mexal S, Berger R, Logel J, Ross RG, Freedman R, Leonard S. Differential regulation of α7 nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers. J Mol Neurosci 2010; 40: 185-95.
65. Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995; 38: 22-33.
66. Davies P, Feisullin S. Postmortem stability of α-bungarotoxin binding sites in mouse and human brain. Brain Res 1981; 216: 449-54.
67. Court JA, Martin-Ruiz C, Graham A, Perry E. Nicotinic receptors in human brain: topography and pathology. J Chem Neuroanat 2000; 20: 281-98.
68. Nordberg A. Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. Biol Psychiatry 2001; 49: 200-10.
69. Wevers A, Schröder H. Nicotinic acetylcholine receptors in Alzheimer's disease. J Alzheimers Dis 1999; 1: 207-19.
70. Burghaus L, Schütz U, Krempel U, Lindstrom J, Schröder H. Loss of nicotinic acetylcholine receptor subunits α4 and α7 in the cerebral cortex of Parkinson patients. Parkinsonism Relat Disord 2003; 9: 243-6.
71. Court J, Spurden D, Lloyd S, et al. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: α-bungarotoxin and nicotine binding in the thalamus. J Neurochem 1999; 73: 1590-7.
72. Guan ZZ, Zhang X, Ravid R, Nordberg A. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J Neurochem 2000; 74: 237-43.
73. Hellström-Lindahl E, Mousavi M, Zhang X, Ravid R, Nordberg A. Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. Brain Res Mol Brain Res 1999; 66: 94-103.
74. Lilja AM, Porras O, Storelli E, Nordberg A, Marutle A. Functional interactions of fibrillar and oligomeric amyloid-β with α7 nicotinic receptors in Alzheimer's disease. J Alzheimers Dis 2011; 23: 335-47.
75. Bencherif M, Lippiello PM. Alpha7 neuronal nicotinic receptors: the missing link to understanding Alzheimer's etiopathology? Med Hypotheses 2010; 74: 281-5.
76. Hoffmeister PG, Donat CK, Schuhmann MU, et al. Traumatic brain injury elicits similar alterations in α7 nicotinic receptor density in two different experimental models. Neuromolecular Medicine 2011; 13: 44-53.
77. Fleminger S, Oliver DL, Lovestone S, Rabe-Hesketh S, Giora A. Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. J Neurol Neurosurg Psychiatry 2003; 74: 857-62.
78. Rosas-Ballina M, Tracey KJ. The neurology of the immune system: neural reflexes regulate immunity. Neuron 2009; 64: 28-32.
79. Conejero-Goldberg C, Davies P, Ulloa L. Alpha7 nicotinic acetylcholine receptor: A link between inflammation and neurodegeneration. Neurosci Biobehav Rev 2008; 32: 693-706.
80. Roncarati R, Scali C, Comery TA, et al. Procognitive and neuroprotective activity of a novel α7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. J Pharmacol Exp Ther 2009; 329: 459-68.
81. Levin ED, Bettegowda C, Blosser J, Gordon J. AR-R17779, and α7 nicotinic agonist, improves learning and memory in rats. Behav Pharmacol 1999; 10: 675-80.
82. Feuerbach D, Lingenhoehl K, Olpe HR, et al. The selective nicotinic acetylcholine receptor α7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain. Neuropharmacology 2009; 56: 254-63.
83. Timmermann DB, Gronlien JH, Kohlhaas KL, et al. An allosteric modulator of the α7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther 2007; 323: 294-307.
84. Faghih R, Gopalakrishnan M, Briggs CA. Allosteric modulators of the α7 nicotinic acetylcholine receptor. J Med Chem 2008; 51: 701-12.
85. Tregellas JR, Tanabe J, Rojas DC, et al. Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Biol Psychiatry 2011; 69: 7-11.
86. Freedman R, Olincy A, Buchanan RW, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008; 165: 1040-7.
87. Thomsen MS, Hansen HH, Timmerman DB, Mikkelsen JD. Cognitive improvement by activation of α7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr Pharm Des 2010; 16: 323-43.
88. Bacher I, Rabin R, Woznica A, Sacco KA, George TP. Nicotinic receptor mechanisms in neuropsychiatric disorders: Therapeutic Implications. Primary Psychiatry 2010; 17: 35-41.
89. Kitagawa H, Takenouchi T, Azuma R, et al. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 2003; 28: 542-51.
90. Hurst RS, Hajos M, Raggenbass M, et al. A novel positive allosteric modulator of the α7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci 2005; 25: 4396-405.
91. Ng HJ, Whittemore ER, Tran MB, et al. Nootropic α7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Proc Natl Acad Sci U S A 2007; 104: 8059-64.
92. Bitner RS, Bunnelle WH, Decker MW, et al. In vivo pharmacological characterization of a novel selective α7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease. J Pharmacol Exp Ther 2010; 334: 875-86.
93. Tietje KR, Anderson DJ, Bitner RS, et al. Preclinical characterization of A-582941: a novel α7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties. CNS Neuroscience & Therapeutics 2008; 14: 65-82.
94. Pacini A, Mannelli LD, Bonaccini L, Ronzoni S, Bartolini A, Ghelardini C. Protective effect of alpha7 nAChR: Behavioural and morphological features on neuropathy. Pain 2010; 150: 542-9.
95. de Jonge WJ, Ulloa L. The α7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br J Pharmacol 2007; 151: 915-29.
96. Mazurov A, Hauser T, Miller CH. Selective α7 nicotinic acetylcholine receptor ligands. Curr Med Chem 2006; 13: 1567-84.
97. Rueger MA, Kracht LW, Hilker R, et al. Role of in vivo imaging of the central nervous system for developing novel drugs. Q J Nucl Med Mol Imaging 2007; 51: 164-81.
98. Roselt P, Meikle S, Kassiou M. The role of positron emission tomography in the discovery and development of new drugs; as studied in laboratory animals. Eur J Drug Metab Pharmacokinet 2004; 29: 1-6.
99. Weber WA, Czernin J, Phelps ME, Herschman HR. Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat Clin Pract Oncol 2008; 5: 44-54.
100. Hargreaves RJ. The role of molecular imaging in drug discovery and development. Clin Pharmacol Ther 2008; 83: 349-53.
101. Lee CM, Farde L. Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci 2006; 27: 310-6.